WO2004080371A3 - Injectable isotonic solution of gatifloxacin pre-diluted in glucose. - Google Patents

Injectable isotonic solution of gatifloxacin pre-diluted in glucose. Download PDF

Info

Publication number
WO2004080371A3
WO2004080371A3 PCT/BR2004/000030 BR2004000030W WO2004080371A3 WO 2004080371 A3 WO2004080371 A3 WO 2004080371A3 BR 2004000030 W BR2004000030 W BR 2004000030W WO 2004080371 A3 WO2004080371 A3 WO 2004080371A3
Authority
WO
WIPO (PCT)
Prior art keywords
diluted
glucose
gatifloxacin
administration
closed system
Prior art date
Application number
PCT/BR2004/000030
Other languages
French (fr)
Other versions
WO2004080371A2 (en
Inventor
Heno Perillo
Original Assignee
Halex Istar Ind Farmaceutica L
Heno Perillo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Halex Istar Ind Farmaceutica L, Heno Perillo filed Critical Halex Istar Ind Farmaceutica L
Publication of WO2004080371A2 publication Critical patent/WO2004080371A2/en
Publication of WO2004080371A3 publication Critical patent/WO2004080371A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/60—1,4-Diazines; Hydrogenated 1,4-diazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Abstract

The present invention has the premise that the use of pre-diluted preparations in closed system reduces the risk of errors in the administration of drugs, reducing the handling phases of the drug by the hospital nursing staff, in addition to reduction in contamination risks. The product obtained by the present invention is presented in the form of gatifloxacin injectable solution pre-diluted in glucose, packed in tri-laminated flexible plastic bag (closed system). Through the formulation pre-diluted in glucose and the closed system, the risks of contamination through the air or contact during the administration are prevented. The formulation is added by 5% of glucose, an isotonic solution, where diluted gatifloxacin is maintained stable when packed in tri-laminated flexible plastic bag. The gatifloxacin-based injectable solution pre-diluted in glucose, is packed in tri-laminated flexible plastic bag of closed system type and shows anti-microbial action of wide spectrum. The method of administration of gatifloxacin-based injectable solution pre-diluted in glucose shows the advantage of administering to patients gatifloxacin-based injectable solution pre-diluted in glucose, packed in tri-laminated flexible plastic bag, of closed system type, thus eliminating the ambient contact with the solution to be administered and preventing the microbial contamination by air or contact during the connection of the administration equipment, thus reducing the risks of errors in the administration of drugs, as well as the reduction of the drug handling phases by the hospital nursing staff.
PCT/BR2004/000030 2003-03-13 2004-03-15 Injectable isotonic solution of gatifloxacin pre-diluted in glucose. WO2004080371A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BRPI0300521-6 2003-03-13
BR0300521A BR0300521A (en) 2003-03-13 2003-03-13 Process for obtaining stable isotonic injectable solution of predefined glucose diluted gatifloxacin, stable injectable solution of predifined glucose diluted gatifloxacin, closed-loop packaging process of the obtained injectable solution, use of closed system for packaging solution of injectable gatifloxacin, use of the prediluted glucose-diluted gatifloxacin solution for injection and method of administration

Publications (2)

Publication Number Publication Date
WO2004080371A2 WO2004080371A2 (en) 2004-09-23
WO2004080371A3 true WO2004080371A3 (en) 2005-09-09

Family

ID=32968093

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2004/000030 WO2004080371A2 (en) 2003-03-13 2004-03-15 Injectable isotonic solution of gatifloxacin pre-diluted in glucose.

Country Status (2)

Country Link
BR (1) BR0300521A (en)
WO (1) WO2004080371A2 (en)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210686A (en) * 1978-06-19 1980-07-01 Baxter Travenol Laboratories Inc. Multi-layered plastic sheeting having high clarity, strength, and resistance to water vapor transmission
CA2419178A1 (en) * 2000-08-14 2003-02-13 Senju Pharmaceutical Co., Ltd. Cytokine production inhibitor

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210686A (en) * 1978-06-19 1980-07-01 Baxter Travenol Laboratories Inc. Multi-layered plastic sheeting having high clarity, strength, and resistance to water vapor transmission
CA2419178A1 (en) * 2000-08-14 2003-02-13 Senju Pharmaceutical Co., Ltd. Cytokine production inhibitor

Also Published As

Publication number Publication date
BR0300521A (en) 2005-03-22
WO2004080371A2 (en) 2004-09-23

Similar Documents

Publication Publication Date Title
PHARMA et al. INT
WO2005044226A3 (en) Lipid formulations for spontaneous drug encapsulation
CY1117668T1 (en) PHARMACEUTICAL RECOMMENDATIONS INCLUDING INSULIN CONTAINED WITH A DICETEPIPERAZINE
HK1088547A1 (en) Once daily dosage forms of trospium trospium
CN105055304A (en) Leave-on skin care and disinfection gel containing composite sterilization component, and preparation method thereof
KR20220037523A (en) Compositions, methods and systems for the treatment of cutaneous disorders
US9345779B2 (en) Aqueous ophthalmic composition
NZ610441A (en) Methods for enhancing oxygenation of jeopardized tissue
EP1250932A1 (en) A stable aqua formulation of interferon, the preparation method and the uses thereof
BR0109747A (en) Use of 5- (2-pyrazinyl) -4-methyl-1-2-dithiol-3-thione (oltipraz) as a medicine, pharmaceutical composition for the prevention and treatment of hepatic fibrosis progression, use of 5- (2- pyrazinyl) -4-methyl-1,2-dithiol-3-thione and method for the prevention and treatment of fibrosis progression and liver cirrhosis
McNeil et al. Domestic metallic mercury poisoning
WO2014129818A1 (en) Pharmaceutical composition for preventing or treating diabetic wound
WO2004080371A3 (en) Injectable isotonic solution of gatifloxacin pre-diluted in glucose.
EP2730292A1 (en) Aqueous ophthalmic composition
Koksal et al. Organophosphate intoxication as a consequence of mouth-to-mouth breathing from an affected case
US20090104292A1 (en) Topical arnica treatment for reducing bruising
CN106620673A (en) Hydrogel for treating infant dental ulcer and preparation method of hydrogel
WO2009150278A1 (en) Pharmaceutical composition of melphalan
CN202909337U (en) Portable type plateau life rescue case
DE60223033D1 (en) IMPROVEMENTS FOR, AND WITH REGARD TO, MODIFIED CELLULOSE FILMS
Langley et al. Anaesthesia for patients with burns injuries
Bawaskar et al. Snakebite, cocktails, and a girl with a stomach ache
Singla et al. Novel approaches for topical delivery of acetazolamide
Guglielmo et al. The exposure of health care workers to ribavirin aerosol
CN107496398A (en) Medical composition and its use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)